Literature DB >> 29579372

Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment.

Mona Amini-Adle1, Muriel Piperno1, Jérémie Tordo1, Luc Thomas1, Stéphane Dalle1, Valérie Dubois2, Aurélien Marabelle3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29579372     DOI： 10.1002/art.40506

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  5 in total

1.  RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.

Authors:  Sang T Kim; William A Murphy; Ana Aparicio; Sumit K Subudhi
Journal:  J Immunother Precis Oncol       Date:  2020-05-14

Review 2.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

3.  Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Authors:  Marie Kostine; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

4.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

5.  Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma.

Authors:  Akihiro Yoshimura; Kazuaki Yamanaka; Rei Tadokoro; Teppei Wakita; Shota Fukae; Takahiro Yoshida; Masahiro Sekiguchi; Hidefumi Kishikawa
Journal:  IJU Case Rep       Date:  2022-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.